Form 4: Altos Venture AG Boosts Onconetix Stake Amidst Reverse Stock Splits

Altos Venture AG, a 10% owner and director of Onconetix, Inc., acquired an additional 241,514 shares of common stock on July 14, 2025, pursuant to a make-whole provision from a prior subscription agreement, following two significant reverse stock splits by the issuer.

Summary

• Altos Venture AG, a 10% owner and director of Onconetix, Inc. (ONCO), acquired 241,514 shares of Onconetix Common Stock on July 14, 2025.
• This acquisition was a result of a "make-whole" provision within a Subscription Agreement dated December 15, 2023.
• The make-whole provision adjusted the price for Units of Common Stock and warrants (purchased on September 24, 2024) by issuing additional shares based on the Issuer's Volume Weighted Average Price (VWAP) during a specified period.
• Following this transaction, Altos Venture AG beneficially owns 273,230 shares of Onconetix Common Stock.
• Onconetix, Inc. effected a 1-for-40 reverse stock split on September 24, 2024, and a 1-for-85 reverse stock split on June 13, 2025.

Sentiment

Score: 3

Explanation: The sentiment is largely negative due to the implications of the 'make-whole' provision (suggesting prior price decline) and the two significant reverse stock splits, which are typically signs of financial distress or poor market performance. While an insider increasing ownership can be positive, the context here points to underlying issues.

Positives

• A significant shareholder and director, Altos Venture AG, has increased its direct ownership in Onconetix, Inc., potentially signaling confidence.
• The acquisition of shares under a "make-whole" provision indicates a pre-agreed mechanism to protect the investor's initial investment value, which can be seen as a positive for investor protection.

Negatives

• The need for a "make-whole" provision and its activation suggests that the stock price may have declined significantly since the initial investment, requiring the issuance of additional shares to compensate the investor.
• The company has undergone two substantial reverse stock splits (1-for-40 on September 24, 2024, and 1-for-85 on June 13, 2025), which often indicate a low stock price and can be perceived negatively by the market as a measure to maintain listing requirements or improve per-share price appearance.

Risks

• The occurrence of two severe reverse stock splits within a short period (September 2024 and June 2025) suggests potential ongoing challenges with the company's stock price and market valuation.
• The "make-whole" provision implies that the initial investment's value may have eroded, leading to dilution for existing shareholders as new shares are issued to compensate the investor.

Future Outlook

The document does not contain explicit forward-looking statements or guidance beyond the completion of the make-whole share issuance.

Industry Context

This Form 4 filing reflects an insider transaction (a 10% owner and director increasing their stake) and the impact of prior financing terms (make-whole provision) and corporate actions (reverse stock splits). In the biotechnology or pharmaceutical industry (implied by "Onconetix"), such actions often occur in companies with volatile stock performance or those undergoing significant R&D phases requiring capital, where investor protection clauses like make-whole provisions are sometimes used. Reverse stock splits are common for companies struggling with low share prices, often to maintain exchange listing requirements.

Related Party Transactions

• The transaction involves Altos Venture AG, a 10% owner and director of Onconetix, Inc., acquiring shares from the issuer, making it a related party transaction.

Stakeholder Impact

• Shareholders: Existing shareholders may experience dilution due to the issuance of additional shares under the make-whole provision. The reverse stock splits also impact share count and per-share metrics.
• Investors (Altos Venture AG): The make-whole provision protected their investment value by providing additional shares, indicating a downside protection mechanism was triggered.

Key Dates

Recommendation

Keywords

Onconetix Inc., ONCO, Altos Venture AG, SEC Form 4, Beneficial Ownership, Stock Acquisition, Make-Whole Provision, Reverse Stock Split, Insider Trading, Equity Investment, Corporate Governance